Moderna Completes Submission of its Biologics License Application to FDA for COVID-19 Vaccine
“We are pleased that our COVID-19 vaccine is showing durable efficacy of 93% through six months after dose 2."Stéphane Bancel, Chief Executive Officer of Moderna Moderna, Inc. (NASDAQ: MRNA) reported completion of the rolling submission process for its Biologics License...